NCT04987086 68Ga-PSMA PET in the Renal Cell Carcinoma
| NCT ID | NCT04987086 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Renal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-06-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2021-06-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma
Eligibility Criteria
Inclusion Criteria: * 2017 AJCC renal cell carcinoma TNM stage III, IV lesions; * In contrast-enhanced CT staging, suspicious metastases were found; * There were no known peripheral or central venous problems; * 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma; * Signed the informed consent form of voluntary participation in clinical trials. Exclusion Criteria: * Age ≤ 18 years old; * Can't stand lying flat in PET / CT examination; * There are contraindications for 68Ga PSMA ligands; * In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test; * Renal function is impaired or hemodialysis is in progress.
Frequently Asked Questions
Who can join the NCT04987086 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Renal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04987086 currently recruiting?
Yes, NCT04987086 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xijing Hospital to inquire about joining.
Where is the NCT04987086 trial being conducted?
This trial is being conducted at Lanzhou, China, Yinchuan, China, Xining, China, Xi'an, China and 5 additional locations.
Who is sponsoring the NCT04987086 clinical trial?
NCT04987086 is sponsored by Xijing Hospital. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.